Calapkulu, M. Et Al. 2019. Anthropometric outcomes in type 2 diabetic patients with new dapagliflozin treatment; actual clinical experience data of six months retrospective glycemic control from single center. DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS , vol.13, no.1 , 284-288.

Calapkulu, M., CANDER, S., ÖZ GÜL, Ö., & ERSOY, C., (2019). Anthropometric outcomes in type 2 diabetic patients with new dapagliflozin treatment; actual clinical experience data of six months retrospective glycemic control from single center. DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS , vol.13, no.1, 284-288.

Calapkulu, Murat Et Al. "Anthropometric outcomes in type 2 diabetic patients with new dapagliflozin treatment; actual clinical experience data of six months retrospective glycemic control from single center," DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS , vol.13, no.1, 284-288, 2019

Calapkulu, Murat Et Al. "Anthropometric outcomes in type 2 diabetic patients with new dapagliflozin treatment; actual clinical experience data of six months retrospective glycemic control from single center." DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS , vol.13, no.1, pp.284-288, 2019

Calapkulu, M. Et Al. (2019) . "Anthropometric outcomes in type 2 diabetic patients with new dapagliflozin treatment; actual clinical experience data of six months retrospective glycemic control from single center." DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS , vol.13, no.1, pp.284-288.

@article{article, author={Murat Calapkulu Et Al. }, title={Anthropometric outcomes in type 2 diabetic patients with new dapagliflozin treatment; actual clinical experience data of six months retrospective glycemic control from single center}, journal={DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS}, year=2019, pages={284-288} }